Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Хроническая болезнь почек и сердечно-сосудистые осложнения: фокус на центральное артериальное давление
Хроническая болезнь почек и сердечно-сосудистые осложнения: фокус на центральное артериальное давление
Муркамилов И.Т., Айтбаев К.А., Сабиров И.С. и др. Хроническая болезнь почек и сердечно-сосудистые осложнения: фокус на центральное артериальное давление. Системные гипертензии. 2017; 14 (1): 58–60.
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Цель обзора – представить данные литературы о роли центрального артериального давления и артериальной жесткости в прогрессировании сердечно-сосудистых осложнений и почечной дисфункции у больных хронической болезнью почек.
Основные положения. В настоящем обзоре обсуждаются патогенетические вопросы повреждающего эффекта повышения центрального артериального давления и артериальной жесткости на сосудистую стенку, развития артериосклероза, атеросклероза и дестабилизации атеросклеротической бляшки в сосудах почек. Все это является непосредственной причиной развития сердечно-сосудистых осложнений и при ренальной дисфункции при хронической болезни почек.
Ключевые слова: хроническая болезнь почек, клубочковая фильтрация, цереброваскулярная патология, эндотелиальная дисфункция.
The main provisions. In this review we discuss the pathogenetic questions damaging effect of increasing CAP and arterial stiffness on the vascular wall, the development of arteriosclerosis, atherosclerosis and destabilization of atherosclerotic plaque in the blood vessels of the kidneys. All this is the direct cause of the CVC and renal dysfunction in CKD.
Key words: chronic kidney disease, glomerular filtration, cerebrovascular pathology, endothelial dysfunction.
Основные положения. В настоящем обзоре обсуждаются патогенетические вопросы повреждающего эффекта повышения центрального артериального давления и артериальной жесткости на сосудистую стенку, развития артериосклероза, атеросклероза и дестабилизации атеросклеротической бляшки в сосудах почек. Все это является непосредственной причиной развития сердечно-сосудистых осложнений и при ренальной дисфункции при хронической болезни почек.
Ключевые слова: хроническая болезнь почек, клубочковая фильтрация, цереброваскулярная патология, эндотелиальная дисфункция.
________________________________________________
The main provisions. In this review we discuss the pathogenetic questions damaging effect of increasing CAP and arterial stiffness on the vascular wall, the development of arteriosclerosis, atherosclerosis and destabilization of atherosclerotic plaque in the blood vessels of the kidneys. All this is the direct cause of the CVC and renal dysfunction in CKD.
Key words: chronic kidney disease, glomerular filtration, cerebrovascular pathology, endothelial dysfunction.
Полный текст
Список литературы
1. Colin D, Jonathan N, Richard P et al. Arterial stiffness in chronic kidney disease: causes and consequences. Heart 2010; 96: 817–823. DOI: 10.1136/hrt.2009.184879.
2. Locatelli F, Pozzoni P, Tentori F et al. Epidemiology of cardiovascular risk in patients with chronic kidney disease. Nephrology Dialysis Transplantation 2003; 18: (Suppl. 7): vii2–vii9. DOI: 10.1093/ndt/gfg1072.
3. Моисеев B.C., Мухин Н.А., Смирнов А.В. Национальные рекомендации: Сердечно-сосудистый риск и хроническая болезнь почек: стратегии кардио-нефропротекции. Евразийский журнал внутренней медицины. 2014; 4 (1): 202–57. / Moiseev B.C., Mukhin N.A., Smirnov A.V. Natsional'nye rekomendatsii: Serdechno-sosudistyi risk i khronicheskaia bolezn' pochek: strategii kardio-nefroprotektsii. Evraziiskii zhurnal vnutrennei meditsiny. 2014; 4 (1): 202–57. [in Russian]
4. The Task Force for the management of arterial hypertension of the European Society of Hypertension and of the European Society of Cardiology. 2013 Guidelines for the management of arterial hypertension. Eur Heart J 2013; 34 (28): 2159–219. DOI: 10.1093/eurheartj/eht151.
5. Recommendations for Improving and Standardizing Vascular Research on Arterial Stiffness. A Scientific Statement From the American Heart Association. Hypertension 2015; 66: 698–722. DOI: 10.1161/ГИП.0000000000000033.
6. Васюк Ю.А., Иванова С.В., Сумин А.Н. и др. Согласованное мнение российских экспертов по оценке артериальной жесткости в клинической практике. Кардиоваскулярная терапия и профилактика. 2016; 2: 20–9. DOI: http://dx.doi.org/10.15829/1728-8800-2016-2-4-19. / Vasiuk Iu.A., Ivanova S.V., Sumin A.N. i dr. Soglasovannoe mnenie rossiiskikh ekspertov po otsenke arterial'noi zhestkosti v klinicheskoi praktike. Kardiovaskuliarnaia terapiia i profilaktika. 2016; 2: 20–9. DOI: http://dx.doi.org/10.15829/1728-8800-2016-2-4-19. [in Russian]
7. Долженко М.Н. Как снизить сердечно-сосудистый риск: роль центрального аортального давления или «голый король»? Ліки України. Medicine of Ukraine. 2016; 9: (205): 4–6. / Dolzhenko M.N. Kak snizit' serdechno-sosudistyi risk: rol' tsentral'nogo aortal'nogo davleniia ili «golyi korol'«? Lіki Ukraїni. Medicine of Ukraine. 2016; 9: (205): 4–6. [in Russian]
8. Конради А.О., Ротарь О.П., Малев Э.Г. и др. Динамика показателей сосудистой жесткости и центрального давления на фоне длительной антигипертензивной терапии. Артериальная гипертензия. 2011; 3: 20–9. / Konradi A.O., Rotar' O.P., Malev E.G. i dr. Dinamika pokazatelei sosudistoi zhestkosti i tsentral'nogo davleniia na fone dlitel'noi antigipertenzivnoi terapii. Arterial'naia gipertenziia. 2011; 3: 20–9. [in Russian]
9. Кобалава Ж.Д., Котовская Ю.В., Кобзев Р.Ю. Характеристики центральной пульсовой волны у молодых мужчин с разными фенотипами артериального давления. Кардиология. 2010; 2: 36–40. / Kobalava Zh.D., Kotovskaia Iu.V., Kobzev R.Iu. Kharakteristiki tsentral'noi pul'sovoi volny u molodykh muzhchin s raznymi fenotipami arterial'nogo davleniia. Kardiologiia. 2010; 2: 36–40. [in Russian]
10. Моисеев В.С., Котовская Ю.В., КобалаваЖ.Д. Центральное артериальное давление: необходимый показатель для оценки сердечно-сосудистого риска и оценки эффективности антигипертензивной терапии? Кардиология. 2007; 9: 15–23. / Moiseev V.S., Kotovskaia Iu.V., KobalavaZh.D. Tsentral'noe arterial'noe davlenie: neobkhodimyi pokazatel' dlia otsenki serdechno-sosudistogo riska i otsenki effektivnosti antigipertenzivnoi terapii? Kardiologiia. 2007; 9: 15–23. [in Russian]
11. Чулков В.С., Вереина Н.К., Синицын С.П. и др. Оценка показателей центрального артериального давления и ригидности артерий у беременных с различными формами артериальной гипертонии. Терапевт. арх. 2014; 12: 15–9. / Chulkov V.S., Vereina N.K., Sinitsyn S.P. i dr. Otsenka pokazatelei tsentral'nogo arterial'nogo davleniia i rigidnosti arterii u beremennykh s razlichnymi formami arterial'noi gipertonii. Terapevt. arkh. 2014; 12: 15–9. [in Russian]
12. Милягин В.А. Центральное пульсовое давление – основная мишень при лечении артериальной гипертонии старшего возраста. Вестник Смоленской государственной медицинской академии. 2014; 13 (3): 5–11. / Miliagin V.A. Tsentral'noe pul'sovoe davlenie – osnovnaia mishen' pri lechenii arterial'noi gipertonii starshego vozrasta. Vestnik Smolenskoi gosudarstvennoi meditsinskoi akademii. 2014; 13 (3): 5–11. [in Russian]
13. Chowienczyk P. Pulse wave analysis, What dothe Numbers Mean? Hypertension 2011; 57: 1051–2. DOI: https://doi.org/10.1161/HYPERTENSIONAHA.111.171504.
14. Nichols WW, O’Rourke MF. McDonald’s blood flow in arteries; Theoretical, experimental and clinical principles. Fifth Edition. Oxford: Oxford University Press, 2005; p. 624.
15. Laurent S, Cockcroft J, Van Bortel L et al.Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 2006; 27: 2588–605.
16. Safar ME, Blacher J, Pannier B et al. Central pulse pressure and mortality in end-stage renal disease. Hypertension 2002; 39: 3: 735–8. PMID:11897754.
17. Boutouyrie P, Achouba A, Trunet P et al. EXPLOR Trialist Group. Amlodipine valsartan combination decreases central systolic blood pressure more effectively than the amlodipineatenolol combination: the EXPLOR study. Hypertension 2010; 55: 1314–22. DOI: 10.1161/HYPERTENSIONAHA.109.148999.
18. London GM, Asmar RG, O’Rourke MF et al. Mechanism(s) of selective systolic blood pressure reduction after a low-dose combination of perindopril/indapamide in hypertensive subjects: comparison with atenolol. J Am Coll Cardiol 2004; 43: 92–9. DOI: 10.1016/j.jacc.2003.07.039.
19. Roman MJ, Kizer JR, Ali T et al Central blood pressure better predicts cardiovascular events than does peripheral blood pressure: The Strong Heart Study. Circulation 2005; 112 (Suppl. II): II-778.
20. Vlachopoulos C, Aznaouridis K, O’Rourke MF et al. Prediction of cardiovascular events and all-cause mortality with central haemodynamics: a systematic review and meta-analysis. Eur Heart J 2010; 31: 1865–71. DOI: http://dx.doi.org/10.1093/eurheartj/ehq024.
21. Nishijima T, Nakayama Y, Tsumura K et al. Pulsatility of ascending aortic blood pressure waveform is associated with an increased risk of coronary heart disease. Am J Hypertens 2001; 14: 469–73. DOI: https://doi.org/10.1016/S0895-7061(00)01288-7.
22. Danchin N, Benetos A, Lopez-Sublet M et al. Aortic pulse pressure is related to the presence and extent artery disease in men undergoing diagnostic coronary angiography: a multicenter study. Am J Hypertens 2004; 17: 129–33. DOI: http://dx.doi.org/10.1016/j.amjhyper.2003.09.010.
23. Chirinos JA, Zambrano JP, Chakko S et al. Relation between ascending aortic pressures and outcomes in patients with angiographically demonstrated coronary artery disease. Am J Cardiol 2005; 96: 645–8. DOI: http://dx.doi.org/10.1016/j.amjcard.2005.04.036.
24. Dart AM, Gatzka CD, Kingwell BA et al. Brachial blood pressure but not carotid arterial waveforms predict cardiovascular events in elderly female hypertensives. Hypertension 2006; 47: 785–90. PMID:16505196.
25. Tsuchikura S, Shoji T, Kimoto E et al. Brachial-ankle pulse wave velocity as an index of central arterial stiffness. J Atheroscler Thromb 2010; 17 (6): 658–65. PMID:20467192.
26. Mitchell GF, Hwang SJ, Vasan RS et al. Arterial stiffness and cardiovascular events: the Framingham Heart Study. Circulation 2010; 121 (4): 505–11. DOI: 10.1161/CIRCULATIONAHA.109.886655.
27. Wang KL, Cheng HM, Chuang SY et al. Central or peripheral systolic or pulse pressure: which best relates to target organs and future mortality? J Hypertens 2009; 27 (3): 461–7. PMID: 19330899.
28. Mancia G, De Backer G, Dominiczak A et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25 (6): 1105–87. DOI: 10.1097/HJH.0b013e3281fc975a.
29. Mancia G, Laurent S, Agabiti-Rosei E et al. Re-appraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009; 27 (11): 2121–58. DOI: 10.1097/HJH.0b013e328333146d.
30. Williams B, Lacy PS, Thom SM et al. CAFE Investigators; Anglo Scandinavian Cardiac Outcomes Trial Investigators; CAFE Steering Committee and Writing Committee Differential impact of blood pressure lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006; 113 (9): 1213–25. DOI: 10.1161/CIRCULATIONAHA.105.595496.
31. Boutouyrie P, Bussy C, Lacolley P et al. Association between local pulse pressure, mean blood pressure, and large-artery remodeling. Circulation 1999; 100 (13): 1387–93. PMID:10500038.
32. Boutouyrie P, Bussy C, Hayoz D et al. Local pulse pressure and regression of arterial wall hypertrophy during long-term antihypertensive treatment. Circulation 2000; 101 (22): 2601–6. DOI: https://doi.org/10.1161/01.CIR.101.22.2601.
33. Roman MJ, Devereux RB. Association of Central and Peripheral Blood Pressures With Intermediate Cardiovascular Phenotypes. Hypertension 2014; 63: 1148–53. DOI: doi.org/10.1161/HYPERTENSIONAHA.114.03361.
34. Roman MJ, Ganau A, Saba PS et al. Impact of arterial stiffening on left ventricular structure. Hypertension 2000; 36 (4): 489–94. PMID:11040224.
35. Gupta AK, Nasothimiou EG, Chang CL et al. Baseline predictors of resistant hypertension in the Anglo Scandinavian Cardiac Outcome Trial (ASCOT): a risk score to identify those at highrisk. J Hypertens 2011; 29 (10): 2004–13. DOI: 10.1097/HJH.0b013e32834a8a42.
36. O’Rourke MF, Safar ME. Relationship between aortic stiffening and microvascular disease in brain and kidney: cause and logic of therapy. Hypertension 2005; 46 (1): 200–4. DOI: 10.1161/01.HYP.0000168052.00426.65.
37. Bogren HG, Buonocore MH. Blood flow measurements in the aorta and major arteries with MR velocity mapping. J Magn Reson Imaging 1994; 4 (2): 119–30. PMID:8180449.
38. Loutzenhiser R, Bidani AK, Wang X. Systolic pressure and the myogenic response of the renal afferent arteriole. Acta Physiol Scand 2004; 181 (4): 407–13. DOI: 10.1111/j.1365-201X.2004.01312.x
39. Bidani AK, Griffin KA, Williamson G et al. Protective importance of the myogenic response in the renal circulation. Hypertension 2009; 54 (2): 393–8. DOI: 10.1161/HYPERTENSIONAHA.109.133777.
40. Griffin KA. Hypertension and kidney damage. J Clin Hypertens (Greenwich) 2006; 8 (3): 209–14. PMID:16523000.
41. Loutzenhiser R, Griffin KA, Bidani AK. Systolic blood pressure as the trigger for the renal myogenic response: protective or autoregulatory? Curr Opin Nephrol Hypertens 2006; 15: 41–9. PMID:16340665
42. Bidani AK, Polichnowski AJ, Loutzenhiser R et al. Renal microvascular dysfunction, hypertension and CKD progression. Curr Opin Nephrol Hypertens 2013; 22: 1–9. DOI: 10.1097/MNH.0b013e32835b36c1.
2. Locatelli F, Pozzoni P, Tentori F et al. Epidemiology of cardiovascular risk in patients with chronic kidney disease. Nephrology Dialysis Transplantation 2003; 18: (Suppl. 7): vii2–vii9. DOI: 10.1093/ndt/gfg1072.
3. Moiseev B.C., Mukhin N.A., Smirnov A.V. Natsional'nye rekomendatsii: Serdechno-sosudistyi risk i khronicheskaia bolezn' pochek: strategii kardio-nefroprotektsii. Evraziiskii zhurnal vnutrennei meditsiny. 2014; 4 (1): 202–57. [in Russian]
4. The Task Force for the management of arterial hypertension of the European Society of Hypertension and of the European Society of Cardiology. 2013 Guidelines for the management of arterial hypertension. Eur Heart J 2013; 34 (28): 2159–219. DOI: 10.1093/eurheartj/eht151.
5. Recommendations for Improving and Standardizing Vascular Research on Arterial Stiffness. A Scientific Statement From the American Heart Association. Hypertension 2015; 66: 698–722. DOI: 10.1161/ГИП.0000000000000033.
6. Vasiuk Iu.A., Ivanova S.V., Sumin A.N. i dr. Soglasovannoe mnenie rossiiskikh ekspertov po otsenke arterial'noi zhestkosti v klinicheskoi praktike. Kardiovaskuliarnaia terapiia i profilaktika. 2016; 2: 20–9. DOI: http://dx.doi.org/10.15829/1728-8800-2016-2-4-19. [in Russian]
7. Dolzhenko M.N. Kak snizit' serdechno-sosudistyi risk: rol' tsentral'nogo aortal'nogo davleniia ili «golyi korol'«? Lіki Ukraїni. Medicine of Ukraine. 2016; 9: (205): 4–6. [in Russian]
8. Konradi A.O., Rotar' O.P., Malev E.G. i dr. Dinamika pokazatelei sosudistoi zhestkosti i tsentral'nogo davleniia na fone dlitel'noi antigipertenzivnoi terapii. Arterial'naia gipertenziia. 2011; 3: 20–9. [in Russian]
9. Kobalava Zh.D., Kotovskaia Iu.V., Kobzev R.Iu. Kharakteristiki tsentral'noi pul'sovoi volny u molodykh muzhchin s raznymi fenotipami arterial'nogo davleniia. Kardiologiia. 2010; 2: 36–40. [in Russian]
10. Moiseev V.S., Kotovskaia Iu.V., KobalavaZh.D. Tsentral'noe arterial'noe davlenie: neobkhodimyi pokazatel' dlia otsenki serdechno-sosudistogo riska i otsenki effektivnosti antigipertenzivnoi terapii? Kardiologiia. 2007; 9: 15–23. [in Russian]
11. Chulkov V.S., Vereina N.K., Sinitsyn S.P. i dr. Otsenka pokazatelei tsentral'nogo arterial'nogo davleniia i rigidnosti arterii u beremennykh s razlichnymi formami arterial'noi gipertonii. Terapevt. arkh. 2014; 12: 15–9. [in Russian]
12. Miliagin V.A. Tsentral'noe pul'sovoe davlenie – osnovnaia mishen' pri lechenii arterial'noi gipertonii starshego vozrasta. Vestnik Smolenskoi gosudarstvennoi meditsinskoi akademii. 2014; 13 (3): 5–11. [in Russian]
13. Chowienczyk P. Pulse wave analysis, What dothe Numbers Mean? Hypertension 2011; 57: 1051–2. DOI: https://doi.org/10.1161/HYPERTENSIONAHA.111.171504.
14. Nichols WW, O’Rourke MF. McDonald’s blood flow in arteries; Theoretical, experimental and clinical principles. Fifth Edition. Oxford: Oxford University Press, 2005; p. 624.
15. Laurent S, Cockcroft J, Van Bortel L et al.Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 2006; 27: 2588–605.
16. Safar ME, Blacher J, Pannier B et al. Central pulse pressure and mortality in end-stage renal disease. Hypertension 2002; 39: 3: 735–8. PMID:11897754.
17. Boutouyrie P, Achouba A, Trunet P et al. EXPLOR Trialist Group. Amlodipine valsartan combination decreases central systolic blood pressure more effectively than the amlodipineatenolol combination: the EXPLOR study. Hypertension 2010; 55: 1314–22. DOI: 10.1161/HYPERTENSIONAHA.109.148999.
18. London GM, Asmar RG, O’Rourke MF et al. Mechanism(s) of selective systolic blood pressure reduction after a low-dose combination of perindopril/indapamide in hypertensive subjects: comparison with atenolol. J Am Coll Cardiol 2004; 43: 92–9. DOI: 10.1016/j.jacc.2003.07.039.
19. Roman MJ, Kizer JR, Ali T et al Central blood pressure better predicts cardiovascular events than does peripheral blood pressure: The Strong Heart Study. Circulation 2005; 112 (Suppl. II): II-778.
20. Vlachopoulos C, Aznaouridis K, O’Rourke MF et al. Prediction of cardiovascular events and all-cause mortality with central haemodynamics: a systematic review and meta-analysis. Eur Heart J 2010; 31: 1865–71. DOI: http://dx.doi.org/10.1093/eurheartj/ehq024.
21. Nishijima T, Nakayama Y, Tsumura K et al. Pulsatility of ascending aortic blood pressure waveform is associated with an increased risk of coronary heart disease. Am J Hypertens 2001; 14: 469–73. DOI: https://doi.org/10.1016/S0895-7061(00)01288-7.
22. Danchin N, Benetos A, Lopez-Sublet M et al. Aortic pulse pressure is related to the presence and extent artery disease in men undergoing diagnostic coronary angiography: a multicenter study. Am J Hypertens 2004; 17: 129–33. DOI: http://dx.doi.org/10.1016/j.amjhyper.2003.09.010.
23. Chirinos JA, Zambrano JP, Chakko S et al. Relation between ascending aortic pressures and outcomes in patients with angiographically demonstrated coronary artery disease. Am J Cardiol 2005; 96: 645–8. DOI: http://dx.doi.org/10.1016/j.amjcard.2005.04.036.
24. Dart AM, Gatzka CD, Kingwell BA et al. Brachial blood pressure but not carotid arterial waveforms predict cardiovascular events in elderly female hypertensives. Hypertension 2006; 47: 785–90. PMID:16505196.
25. Tsuchikura S, Shoji T, Kimoto E et al. Brachial-ankle pulse wave velocity as an index of central arterial stiffness. J Atheroscler Thromb 2010; 17 (6): 658–65. PMID:20467192.
26. Mitchell GF, Hwang SJ, Vasan RS et al. Arterial stiffness and cardiovascular events: the Framingham Heart Study. Circulation 2010; 121 (4): 505–11. DOI: 10.1161/CIRCULATIONAHA.109.886655.
27. Wang KL, Cheng HM, Chuang SY et al. Central or peripheral systolic or pulse pressure: which best relates to target organs and future mortality? J Hypertens 2009; 27 (3): 461–7. PMID: 19330899.
28. Mancia G, De Backer G, Dominiczak A et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25 (6): 1105–87. DOI: 10.1097/HJH.0b013e3281fc975a.
29. Mancia G, Laurent S, Agabiti-Rosei E et al. Re-appraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009; 27 (11): 2121–58. DOI: 10.1097/HJH.0b013e328333146d.
30. Williams B, Lacy PS, Thom SM et al. CAFE Investigators; Anglo Scandinavian Cardiac Outcomes Trial Investigators; CAFE Steering Committee and Writing Committee Differential impact of blood pressure lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006; 113 (9): 1213–25. DOI: 10.1161/CIRCULATIONAHA.105.595496.
31. Boutouyrie P, Bussy C, Lacolley P et al. Association between local pulse pressure, mean blood pressure, and large-artery remodeling. Circulation 1999; 100 (13): 1387–93. PMID:10500038.
32. Boutouyrie P, Bussy C, Hayoz D et al. Local pulse pressure and regression of arterial wall hypertrophy during long-term antihypertensive treatment. Circulation 2000; 101 (22): 2601–6. DOI: https://doi.org/10.1161/01.CIR.101.22.2601.
33. Roman MJ, Devereux RB. Association of Central and Peripheral Blood Pressures With Intermediate Cardiovascular Phenotypes. Hypertension 2014; 63: 1148–53. DOI: doi.org/10.1161/HYPERTENSIONAHA.114.03361.
34. Roman MJ, Ganau A, Saba PS et al. Impact of arterial stiffening on left ventricular structure. Hypertension 2000; 36 (4): 489–94. PMID:11040224.
35. Gupta AK, Nasothimiou EG, Chang CL et al. Baseline predictors of resistant hypertension in the Anglo Scandinavian Cardiac Outcome Trial (ASCOT): a risk score to identify those at highrisk. J Hypertens 2011; 29 (10): 2004–13. DOI: 10.1097/HJH.0b013e32834a8a42.
36. O’Rourke MF, Safar ME. Relationship between aortic stiffening and microvascular disease in brain and kidney: cause and logic of therapy. Hypertension 2005; 46 (1): 200–4. DOI: 10.1161/01.HYP.0000168052.00426.65.
37. Bogren HG, Buonocore MH. Blood flow measurements in the aorta and major arteries with MR velocity mapping. J Magn Reson Imaging 1994; 4 (2): 119–30. PMID:8180449.
38. Loutzenhiser R, Bidani AK, Wang X. Systolic pressure and the myogenic response of the renal afferent arteriole. Acta Physiol Scand 2004; 181 (4): 407–13. DOI: 10.1111/j.1365-201X.2004.01312.x
39. Bidani AK, Griffin KA, Williamson G et al. Protective importance of the myogenic response in the renal circulation. Hypertension 2009; 54 (2): 393–8. DOI: 10.1161/HYPERTENSIONAHA.109.133777.
40. Griffin KA. Hypertension and kidney damage. J Clin Hypertens (Greenwich) 2006; 8 (3): 209–14. PMID:16523000.
41. Loutzenhiser R, Griffin KA, Bidani AK. Systolic blood pressure as the trigger for the renal myogenic response: protective or autoregulatory? Curr Opin Nephrol Hypertens 2006; 15: 41–9. PMID:16340665
42. Bidani AK, Polichnowski AJ, Loutzenhiser R et al. Renal microvascular dysfunction, hypertension and CKD progression. Curr Opin Nephrol Hypertens 2013; 22: 1–9. DOI: 10.1097/MNH.0b013e32835b36c1.
2. Locatelli F, Pozzoni P, Tentori F et al. Epidemiology of cardiovascular risk in patients with chronic kidney disease. Nephrology Dialysis Transplantation 2003; 18: (Suppl. 7): vii2–vii9. DOI: 10.1093/ndt/gfg1072.
3. Моисеев B.C., Мухин Н.А., Смирнов А.В. Национальные рекомендации: Сердечно-сосудистый риск и хроническая болезнь почек: стратегии кардио-нефропротекции. Евразийский журнал внутренней медицины. 2014; 4 (1): 202–57. / Moiseev B.C., Mukhin N.A., Smirnov A.V. Natsional'nye rekomendatsii: Serdechno-sosudistyi risk i khronicheskaia bolezn' pochek: strategii kardio-nefroprotektsii. Evraziiskii zhurnal vnutrennei meditsiny. 2014; 4 (1): 202–57. [in Russian]
4. The Task Force for the management of arterial hypertension of the European Society of Hypertension and of the European Society of Cardiology. 2013 Guidelines for the management of arterial hypertension. Eur Heart J 2013; 34 (28): 2159–219. DOI: 10.1093/eurheartj/eht151.
5. Recommendations for Improving and Standardizing Vascular Research on Arterial Stiffness. A Scientific Statement From the American Heart Association. Hypertension 2015; 66: 698–722. DOI: 10.1161/ГИП.0000000000000033.
6. Васюк Ю.А., Иванова С.В., Сумин А.Н. и др. Согласованное мнение российских экспертов по оценке артериальной жесткости в клинической практике. Кардиоваскулярная терапия и профилактика. 2016; 2: 20–9. DOI: http://dx.doi.org/10.15829/1728-8800-2016-2-4-19. / Vasiuk Iu.A., Ivanova S.V., Sumin A.N. i dr. Soglasovannoe mnenie rossiiskikh ekspertov po otsenke arterial'noi zhestkosti v klinicheskoi praktike. Kardiovaskuliarnaia terapiia i profilaktika. 2016; 2: 20–9. DOI: http://dx.doi.org/10.15829/1728-8800-2016-2-4-19. [in Russian]
7. Долженко М.Н. Как снизить сердечно-сосудистый риск: роль центрального аортального давления или «голый король»? Ліки України. Medicine of Ukraine. 2016; 9: (205): 4–6. / Dolzhenko M.N. Kak snizit' serdechno-sosudistyi risk: rol' tsentral'nogo aortal'nogo davleniia ili «golyi korol'«? Lіki Ukraїni. Medicine of Ukraine. 2016; 9: (205): 4–6. [in Russian]
8. Конради А.О., Ротарь О.П., Малев Э.Г. и др. Динамика показателей сосудистой жесткости и центрального давления на фоне длительной антигипертензивной терапии. Артериальная гипертензия. 2011; 3: 20–9. / Konradi A.O., Rotar' O.P., Malev E.G. i dr. Dinamika pokazatelei sosudistoi zhestkosti i tsentral'nogo davleniia na fone dlitel'noi antigipertenzivnoi terapii. Arterial'naia gipertenziia. 2011; 3: 20–9. [in Russian]
9. Кобалава Ж.Д., Котовская Ю.В., Кобзев Р.Ю. Характеристики центральной пульсовой волны у молодых мужчин с разными фенотипами артериального давления. Кардиология. 2010; 2: 36–40. / Kobalava Zh.D., Kotovskaia Iu.V., Kobzev R.Iu. Kharakteristiki tsentral'noi pul'sovoi volny u molodykh muzhchin s raznymi fenotipami arterial'nogo davleniia. Kardiologiia. 2010; 2: 36–40. [in Russian]
10. Моисеев В.С., Котовская Ю.В., КобалаваЖ.Д. Центральное артериальное давление: необходимый показатель для оценки сердечно-сосудистого риска и оценки эффективности антигипертензивной терапии? Кардиология. 2007; 9: 15–23. / Moiseev V.S., Kotovskaia Iu.V., KobalavaZh.D. Tsentral'noe arterial'noe davlenie: neobkhodimyi pokazatel' dlia otsenki serdechno-sosudistogo riska i otsenki effektivnosti antigipertenzivnoi terapii? Kardiologiia. 2007; 9: 15–23. [in Russian]
11. Чулков В.С., Вереина Н.К., Синицын С.П. и др. Оценка показателей центрального артериального давления и ригидности артерий у беременных с различными формами артериальной гипертонии. Терапевт. арх. 2014; 12: 15–9. / Chulkov V.S., Vereina N.K., Sinitsyn S.P. i dr. Otsenka pokazatelei tsentral'nogo arterial'nogo davleniia i rigidnosti arterii u beremennykh s razlichnymi formami arterial'noi gipertonii. Terapevt. arkh. 2014; 12: 15–9. [in Russian]
12. Милягин В.А. Центральное пульсовое давление – основная мишень при лечении артериальной гипертонии старшего возраста. Вестник Смоленской государственной медицинской академии. 2014; 13 (3): 5–11. / Miliagin V.A. Tsentral'noe pul'sovoe davlenie – osnovnaia mishen' pri lechenii arterial'noi gipertonii starshego vozrasta. Vestnik Smolenskoi gosudarstvennoi meditsinskoi akademii. 2014; 13 (3): 5–11. [in Russian]
13. Chowienczyk P. Pulse wave analysis, What dothe Numbers Mean? Hypertension 2011; 57: 1051–2. DOI: https://doi.org/10.1161/HYPERTENSIONAHA.111.171504.
14. Nichols WW, O’Rourke MF. McDonald’s blood flow in arteries; Theoretical, experimental and clinical principles. Fifth Edition. Oxford: Oxford University Press, 2005; p. 624.
15. Laurent S, Cockcroft J, Van Bortel L et al.Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 2006; 27: 2588–605.
16. Safar ME, Blacher J, Pannier B et al. Central pulse pressure and mortality in end-stage renal disease. Hypertension 2002; 39: 3: 735–8. PMID:11897754.
17. Boutouyrie P, Achouba A, Trunet P et al. EXPLOR Trialist Group. Amlodipine valsartan combination decreases central systolic blood pressure more effectively than the amlodipineatenolol combination: the EXPLOR study. Hypertension 2010; 55: 1314–22. DOI: 10.1161/HYPERTENSIONAHA.109.148999.
18. London GM, Asmar RG, O’Rourke MF et al. Mechanism(s) of selective systolic blood pressure reduction after a low-dose combination of perindopril/indapamide in hypertensive subjects: comparison with atenolol. J Am Coll Cardiol 2004; 43: 92–9. DOI: 10.1016/j.jacc.2003.07.039.
19. Roman MJ, Kizer JR, Ali T et al Central blood pressure better predicts cardiovascular events than does peripheral blood pressure: The Strong Heart Study. Circulation 2005; 112 (Suppl. II): II-778.
20. Vlachopoulos C, Aznaouridis K, O’Rourke MF et al. Prediction of cardiovascular events and all-cause mortality with central haemodynamics: a systematic review and meta-analysis. Eur Heart J 2010; 31: 1865–71. DOI: http://dx.doi.org/10.1093/eurheartj/ehq024.
21. Nishijima T, Nakayama Y, Tsumura K et al. Pulsatility of ascending aortic blood pressure waveform is associated with an increased risk of coronary heart disease. Am J Hypertens 2001; 14: 469–73. DOI: https://doi.org/10.1016/S0895-7061(00)01288-7.
22. Danchin N, Benetos A, Lopez-Sublet M et al. Aortic pulse pressure is related to the presence and extent artery disease in men undergoing diagnostic coronary angiography: a multicenter study. Am J Hypertens 2004; 17: 129–33. DOI: http://dx.doi.org/10.1016/j.amjhyper.2003.09.010.
23. Chirinos JA, Zambrano JP, Chakko S et al. Relation between ascending aortic pressures and outcomes in patients with angiographically demonstrated coronary artery disease. Am J Cardiol 2005; 96: 645–8. DOI: http://dx.doi.org/10.1016/j.amjcard.2005.04.036.
24. Dart AM, Gatzka CD, Kingwell BA et al. Brachial blood pressure but not carotid arterial waveforms predict cardiovascular events in elderly female hypertensives. Hypertension 2006; 47: 785–90. PMID:16505196.
25. Tsuchikura S, Shoji T, Kimoto E et al. Brachial-ankle pulse wave velocity as an index of central arterial stiffness. J Atheroscler Thromb 2010; 17 (6): 658–65. PMID:20467192.
26. Mitchell GF, Hwang SJ, Vasan RS et al. Arterial stiffness and cardiovascular events: the Framingham Heart Study. Circulation 2010; 121 (4): 505–11. DOI: 10.1161/CIRCULATIONAHA.109.886655.
27. Wang KL, Cheng HM, Chuang SY et al. Central or peripheral systolic or pulse pressure: which best relates to target organs and future mortality? J Hypertens 2009; 27 (3): 461–7. PMID: 19330899.
28. Mancia G, De Backer G, Dominiczak A et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25 (6): 1105–87. DOI: 10.1097/HJH.0b013e3281fc975a.
29. Mancia G, Laurent S, Agabiti-Rosei E et al. Re-appraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009; 27 (11): 2121–58. DOI: 10.1097/HJH.0b013e328333146d.
30. Williams B, Lacy PS, Thom SM et al. CAFE Investigators; Anglo Scandinavian Cardiac Outcomes Trial Investigators; CAFE Steering Committee and Writing Committee Differential impact of blood pressure lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006; 113 (9): 1213–25. DOI: 10.1161/CIRCULATIONAHA.105.595496.
31. Boutouyrie P, Bussy C, Lacolley P et al. Association between local pulse pressure, mean blood pressure, and large-artery remodeling. Circulation 1999; 100 (13): 1387–93. PMID:10500038.
32. Boutouyrie P, Bussy C, Hayoz D et al. Local pulse pressure and regression of arterial wall hypertrophy during long-term antihypertensive treatment. Circulation 2000; 101 (22): 2601–6. DOI: https://doi.org/10.1161/01.CIR.101.22.2601.
33. Roman MJ, Devereux RB. Association of Central and Peripheral Blood Pressures With Intermediate Cardiovascular Phenotypes. Hypertension 2014; 63: 1148–53. DOI: doi.org/10.1161/HYPERTENSIONAHA.114.03361.
34. Roman MJ, Ganau A, Saba PS et al. Impact of arterial stiffening on left ventricular structure. Hypertension 2000; 36 (4): 489–94. PMID:11040224.
35. Gupta AK, Nasothimiou EG, Chang CL et al. Baseline predictors of resistant hypertension in the Anglo Scandinavian Cardiac Outcome Trial (ASCOT): a risk score to identify those at highrisk. J Hypertens 2011; 29 (10): 2004–13. DOI: 10.1097/HJH.0b013e32834a8a42.
36. O’Rourke MF, Safar ME. Relationship between aortic stiffening and microvascular disease in brain and kidney: cause and logic of therapy. Hypertension 2005; 46 (1): 200–4. DOI: 10.1161/01.HYP.0000168052.00426.65.
37. Bogren HG, Buonocore MH. Blood flow measurements in the aorta and major arteries with MR velocity mapping. J Magn Reson Imaging 1994; 4 (2): 119–30. PMID:8180449.
38. Loutzenhiser R, Bidani AK, Wang X. Systolic pressure and the myogenic response of the renal afferent arteriole. Acta Physiol Scand 2004; 181 (4): 407–13. DOI: 10.1111/j.1365-201X.2004.01312.x
39. Bidani AK, Griffin KA, Williamson G et al. Protective importance of the myogenic response in the renal circulation. Hypertension 2009; 54 (2): 393–8. DOI: 10.1161/HYPERTENSIONAHA.109.133777.
40. Griffin KA. Hypertension and kidney damage. J Clin Hypertens (Greenwich) 2006; 8 (3): 209–14. PMID:16523000.
41. Loutzenhiser R, Griffin KA, Bidani AK. Systolic blood pressure as the trigger for the renal myogenic response: protective or autoregulatory? Curr Opin Nephrol Hypertens 2006; 15: 41–9. PMID:16340665
42. Bidani AK, Polichnowski AJ, Loutzenhiser R et al. Renal microvascular dysfunction, hypertension and CKD progression. Curr Opin Nephrol Hypertens 2013; 22: 1–9. DOI: 10.1097/MNH.0b013e32835b36c1.
________________________________________________
2. Locatelli F, Pozzoni P, Tentori F et al. Epidemiology of cardiovascular risk in patients with chronic kidney disease. Nephrology Dialysis Transplantation 2003; 18: (Suppl. 7): vii2–vii9. DOI: 10.1093/ndt/gfg1072.
3. Moiseev B.C., Mukhin N.A., Smirnov A.V. Natsional'nye rekomendatsii: Serdechno-sosudistyi risk i khronicheskaia bolezn' pochek: strategii kardio-nefroprotektsii. Evraziiskii zhurnal vnutrennei meditsiny. 2014; 4 (1): 202–57. [in Russian]
4. The Task Force for the management of arterial hypertension of the European Society of Hypertension and of the European Society of Cardiology. 2013 Guidelines for the management of arterial hypertension. Eur Heart J 2013; 34 (28): 2159–219. DOI: 10.1093/eurheartj/eht151.
5. Recommendations for Improving and Standardizing Vascular Research on Arterial Stiffness. A Scientific Statement From the American Heart Association. Hypertension 2015; 66: 698–722. DOI: 10.1161/ГИП.0000000000000033.
6. Vasiuk Iu.A., Ivanova S.V., Sumin A.N. i dr. Soglasovannoe mnenie rossiiskikh ekspertov po otsenke arterial'noi zhestkosti v klinicheskoi praktike. Kardiovaskuliarnaia terapiia i profilaktika. 2016; 2: 20–9. DOI: http://dx.doi.org/10.15829/1728-8800-2016-2-4-19. [in Russian]
7. Dolzhenko M.N. Kak snizit' serdechno-sosudistyi risk: rol' tsentral'nogo aortal'nogo davleniia ili «golyi korol'«? Lіki Ukraїni. Medicine of Ukraine. 2016; 9: (205): 4–6. [in Russian]
8. Konradi A.O., Rotar' O.P., Malev E.G. i dr. Dinamika pokazatelei sosudistoi zhestkosti i tsentral'nogo davleniia na fone dlitel'noi antigipertenzivnoi terapii. Arterial'naia gipertenziia. 2011; 3: 20–9. [in Russian]
9. Kobalava Zh.D., Kotovskaia Iu.V., Kobzev R.Iu. Kharakteristiki tsentral'noi pul'sovoi volny u molodykh muzhchin s raznymi fenotipami arterial'nogo davleniia. Kardiologiia. 2010; 2: 36–40. [in Russian]
10. Moiseev V.S., Kotovskaia Iu.V., KobalavaZh.D. Tsentral'noe arterial'noe davlenie: neobkhodimyi pokazatel' dlia otsenki serdechno-sosudistogo riska i otsenki effektivnosti antigipertenzivnoi terapii? Kardiologiia. 2007; 9: 15–23. [in Russian]
11. Chulkov V.S., Vereina N.K., Sinitsyn S.P. i dr. Otsenka pokazatelei tsentral'nogo arterial'nogo davleniia i rigidnosti arterii u beremennykh s razlichnymi formami arterial'noi gipertonii. Terapevt. arkh. 2014; 12: 15–9. [in Russian]
12. Miliagin V.A. Tsentral'noe pul'sovoe davlenie – osnovnaia mishen' pri lechenii arterial'noi gipertonii starshego vozrasta. Vestnik Smolenskoi gosudarstvennoi meditsinskoi akademii. 2014; 13 (3): 5–11. [in Russian]
13. Chowienczyk P. Pulse wave analysis, What dothe Numbers Mean? Hypertension 2011; 57: 1051–2. DOI: https://doi.org/10.1161/HYPERTENSIONAHA.111.171504.
14. Nichols WW, O’Rourke MF. McDonald’s blood flow in arteries; Theoretical, experimental and clinical principles. Fifth Edition. Oxford: Oxford University Press, 2005; p. 624.
15. Laurent S, Cockcroft J, Van Bortel L et al.Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 2006; 27: 2588–605.
16. Safar ME, Blacher J, Pannier B et al. Central pulse pressure and mortality in end-stage renal disease. Hypertension 2002; 39: 3: 735–8. PMID:11897754.
17. Boutouyrie P, Achouba A, Trunet P et al. EXPLOR Trialist Group. Amlodipine valsartan combination decreases central systolic blood pressure more effectively than the amlodipineatenolol combination: the EXPLOR study. Hypertension 2010; 55: 1314–22. DOI: 10.1161/HYPERTENSIONAHA.109.148999.
18. London GM, Asmar RG, O’Rourke MF et al. Mechanism(s) of selective systolic blood pressure reduction after a low-dose combination of perindopril/indapamide in hypertensive subjects: comparison with atenolol. J Am Coll Cardiol 2004; 43: 92–9. DOI: 10.1016/j.jacc.2003.07.039.
19. Roman MJ, Kizer JR, Ali T et al Central blood pressure better predicts cardiovascular events than does peripheral blood pressure: The Strong Heart Study. Circulation 2005; 112 (Suppl. II): II-778.
20. Vlachopoulos C, Aznaouridis K, O’Rourke MF et al. Prediction of cardiovascular events and all-cause mortality with central haemodynamics: a systematic review and meta-analysis. Eur Heart J 2010; 31: 1865–71. DOI: http://dx.doi.org/10.1093/eurheartj/ehq024.
21. Nishijima T, Nakayama Y, Tsumura K et al. Pulsatility of ascending aortic blood pressure waveform is associated with an increased risk of coronary heart disease. Am J Hypertens 2001; 14: 469–73. DOI: https://doi.org/10.1016/S0895-7061(00)01288-7.
22. Danchin N, Benetos A, Lopez-Sublet M et al. Aortic pulse pressure is related to the presence and extent artery disease in men undergoing diagnostic coronary angiography: a multicenter study. Am J Hypertens 2004; 17: 129–33. DOI: http://dx.doi.org/10.1016/j.amjhyper.2003.09.010.
23. Chirinos JA, Zambrano JP, Chakko S et al. Relation between ascending aortic pressures and outcomes in patients with angiographically demonstrated coronary artery disease. Am J Cardiol 2005; 96: 645–8. DOI: http://dx.doi.org/10.1016/j.amjcard.2005.04.036.
24. Dart AM, Gatzka CD, Kingwell BA et al. Brachial blood pressure but not carotid arterial waveforms predict cardiovascular events in elderly female hypertensives. Hypertension 2006; 47: 785–90. PMID:16505196.
25. Tsuchikura S, Shoji T, Kimoto E et al. Brachial-ankle pulse wave velocity as an index of central arterial stiffness. J Atheroscler Thromb 2010; 17 (6): 658–65. PMID:20467192.
26. Mitchell GF, Hwang SJ, Vasan RS et al. Arterial stiffness and cardiovascular events: the Framingham Heart Study. Circulation 2010; 121 (4): 505–11. DOI: 10.1161/CIRCULATIONAHA.109.886655.
27. Wang KL, Cheng HM, Chuang SY et al. Central or peripheral systolic or pulse pressure: which best relates to target organs and future mortality? J Hypertens 2009; 27 (3): 461–7. PMID: 19330899.
28. Mancia G, De Backer G, Dominiczak A et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25 (6): 1105–87. DOI: 10.1097/HJH.0b013e3281fc975a.
29. Mancia G, Laurent S, Agabiti-Rosei E et al. Re-appraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009; 27 (11): 2121–58. DOI: 10.1097/HJH.0b013e328333146d.
30. Williams B, Lacy PS, Thom SM et al. CAFE Investigators; Anglo Scandinavian Cardiac Outcomes Trial Investigators; CAFE Steering Committee and Writing Committee Differential impact of blood pressure lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006; 113 (9): 1213–25. DOI: 10.1161/CIRCULATIONAHA.105.595496.
31. Boutouyrie P, Bussy C, Lacolley P et al. Association between local pulse pressure, mean blood pressure, and large-artery remodeling. Circulation 1999; 100 (13): 1387–93. PMID:10500038.
32. Boutouyrie P, Bussy C, Hayoz D et al. Local pulse pressure and regression of arterial wall hypertrophy during long-term antihypertensive treatment. Circulation 2000; 101 (22): 2601–6. DOI: https://doi.org/10.1161/01.CIR.101.22.2601.
33. Roman MJ, Devereux RB. Association of Central and Peripheral Blood Pressures With Intermediate Cardiovascular Phenotypes. Hypertension 2014; 63: 1148–53. DOI: doi.org/10.1161/HYPERTENSIONAHA.114.03361.
34. Roman MJ, Ganau A, Saba PS et al. Impact of arterial stiffening on left ventricular structure. Hypertension 2000; 36 (4): 489–94. PMID:11040224.
35. Gupta AK, Nasothimiou EG, Chang CL et al. Baseline predictors of resistant hypertension in the Anglo Scandinavian Cardiac Outcome Trial (ASCOT): a risk score to identify those at highrisk. J Hypertens 2011; 29 (10): 2004–13. DOI: 10.1097/HJH.0b013e32834a8a42.
36. O’Rourke MF, Safar ME. Relationship between aortic stiffening and microvascular disease in brain and kidney: cause and logic of therapy. Hypertension 2005; 46 (1): 200–4. DOI: 10.1161/01.HYP.0000168052.00426.65.
37. Bogren HG, Buonocore MH. Blood flow measurements in the aorta and major arteries with MR velocity mapping. J Magn Reson Imaging 1994; 4 (2): 119–30. PMID:8180449.
38. Loutzenhiser R, Bidani AK, Wang X. Systolic pressure and the myogenic response of the renal afferent arteriole. Acta Physiol Scand 2004; 181 (4): 407–13. DOI: 10.1111/j.1365-201X.2004.01312.x
39. Bidani AK, Griffin KA, Williamson G et al. Protective importance of the myogenic response in the renal circulation. Hypertension 2009; 54 (2): 393–8. DOI: 10.1161/HYPERTENSIONAHA.109.133777.
40. Griffin KA. Hypertension and kidney damage. J Clin Hypertens (Greenwich) 2006; 8 (3): 209–14. PMID:16523000.
41. Loutzenhiser R, Griffin KA, Bidani AK. Systolic blood pressure as the trigger for the renal myogenic response: protective or autoregulatory? Curr Opin Nephrol Hypertens 2006; 15: 41–9. PMID:16340665
42. Bidani AK, Polichnowski AJ, Loutzenhiser R et al. Renal microvascular dysfunction, hypertension and CKD progression. Curr Opin Nephrol Hypertens 2013; 22: 1–9. DOI: 10.1097/MNH.0b013e32835b36c1.
Авторы
И.Т.Муркамилов*1, К.А.Айтбаев2, И.С.Сабиров3, В.В.Фомин4, Ф.А.Юсупов5
1 Кыргызская государственная медицинская академия имени И.К.Ахунбаева. 720020, Кыргызская Республика, Бишкек, ул. Ахунбаева, д. 92;
2 Национальный центр кардиологии и терапии им. академика Мирсаида Миррахимова Министерства здравоохранения Кыргызской Республики. 720040, Кыргызская Республика, Бишкек, ул. Тоголок Молдо, д. 3;
3 Кыргызско-российский славянский университет им. Б.Н.Ельцина Министерства образования и науки Кыргызской Республики. 720000, Кыргызская Республика, Бишкек, ул. Киевская, д. 44;
4 ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М.Сеченова» Минздрава России. 119991, Россия, Москва, ул. Трубецкая, д. 8, стр. 2;
5 Ошский государственный университет. 723500, Кыргызская Республика, Ош, ул. Ленина, д. 331
*murkamilov.i@mail.ru
1 Kyrgyz State Medical Academy named after I.K.Akhunbaeva. 720020, Kyrgyzstan, Bishkek, ul. Akhunbaeva, d. 92;
2 National Center of Cardiology and Internal Medicine named after academician Mirsaid Mirrahimov. 720040, Kyrgyzstan, Bishkek, ul. Togolok Moldo, d. 3;
3 Kyrgyz Russian Slavic University. 720000, Kyrgyzstan, Bishkek, ul. Kievskaia, d. 44;
4 I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation. 119991, Russian Federation, Moscow, ul. Trubetskaia, d. 8, str. 2;
5 State University of Osh city. 723500, Kyrgyzstan, Osh, ul. Lenina, d. 331
*murkamilov.i@mail.ru
1 Кыргызская государственная медицинская академия имени И.К.Ахунбаева. 720020, Кыргызская Республика, Бишкек, ул. Ахунбаева, д. 92;
2 Национальный центр кардиологии и терапии им. академика Мирсаида Миррахимова Министерства здравоохранения Кыргызской Республики. 720040, Кыргызская Республика, Бишкек, ул. Тоголок Молдо, д. 3;
3 Кыргызско-российский славянский университет им. Б.Н.Ельцина Министерства образования и науки Кыргызской Республики. 720000, Кыргызская Республика, Бишкек, ул. Киевская, д. 44;
4 ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М.Сеченова» Минздрава России. 119991, Россия, Москва, ул. Трубецкая, д. 8, стр. 2;
5 Ошский государственный университет. 723500, Кыргызская Республика, Ош, ул. Ленина, д. 331
*murkamilov.i@mail.ru
________________________________________________
1 Kyrgyz State Medical Academy named after I.K.Akhunbaeva. 720020, Kyrgyzstan, Bishkek, ul. Akhunbaeva, d. 92;
2 National Center of Cardiology and Internal Medicine named after academician Mirsaid Mirrahimov. 720040, Kyrgyzstan, Bishkek, ul. Togolok Moldo, d. 3;
3 Kyrgyz Russian Slavic University. 720000, Kyrgyzstan, Bishkek, ul. Kievskaia, d. 44;
4 I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation. 119991, Russian Federation, Moscow, ul. Trubetskaia, d. 8, str. 2;
5 State University of Osh city. 723500, Kyrgyzstan, Osh, ul. Lenina, d. 331
*murkamilov.i@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.